Table 89.7Single-Agent Chemotherapy in Malignant Mesothelioma*

AgentDose mg/m2No PTSNo CRNo PRTotal RespResp. Rate (%)Med. Surv. (mo)Ref.
Acivicin20 × 31900002
20 × 3210000797
3000249
Total430000
Aclacinomycin-A85–100100111088
Amsacrine1201701162
5-Azacytidine100–1503022286
100–150300063
Total602233
Bleomycin2019022115
15 × 5300063
Total220229
CB3717300–40017011644
Carboplatin40090222245
300–4001711212174
150 × 331145168203
4004003387282
Total972101212
Chlorozotocin1501000005
Cisplatin15 × 5610117231
1009101111275
12024033135181
10035055147.5314
Total74281014
Cisplatin high-dose40/d × 51203325207
80/wk × 61405536199
Cyclophosphamide1,500210000245
2,500130332366
Total340339
Cycloleucine§702229156
Detorubicin40 × 321279431770
Dihydro-azacytidine5,0001200006.281
1,500 × 5d41167176.7285a
1,500 × 5d510224423a
Total1041899
Docetaxel10020011526a
Don#50 × 57000088
Doxorubicin505235100146
705120235
60–758202252829
110119283
60210000245
60–7051257147.5156
Total1126101715
Diaziquone25–30200000687
Docetaxel205
Edatrexate80201452526
Epirubicin110480771510173
752101157.5163
Total6908812
Etoposide150 × 3 IV4702247230a
100/d PO*4103379.5
Total880556
Fluorouracil|3202107
2202129
**2001157120
Total2541520
Gemcitabine1250/wk × 32702278276a
Ifosfamide1,200 × 5170442493
2,000 × 42602286.5315
3,000 × 3260114105a
Total6907710
Methotrexate††9044441384
‡‡60121223711244a
Mitomycin10190442119
Mitoxanthrone1228112792
Phase 12000111
14340113274
Total641235
Paclitaxel250/24h3503395285
200/3h25000010276
Total600335
PCNU60–903400003.8300
Pirarubicin35–708123386.5248
7035033910.5135
Total4315614
Topotecan1.5/d × 52200007.5163a
Trimetrexate617022125284
1034044128.9284
Total5106612
Vinblastine1.4 × 5200000373
Vincristine1.32300007172
Vindesine3170116140
2 × 221000030
Total380113
Vinorelbine301904421251a
*

Single case reports excluded

CB3717 = N10-propargyl-5,8 dideazafolic acid

mean (not median)

§

300mg/kg/d × 8 days

#

DON = 6-diazo-5-oxo-L-norleucine

|

variable doses (Gerner)

**

10–15 mg/kg × 5 days IV bolus

††

18–50 g with leucovorin

‡‡

3 g with leucovorin every 10 days × 4

No PTS = number of patients; CR = complete response; PR = partial response; RESP = response; MED SURV = median survival (mo = months)

From: Chapter 89, Malignant Mesothelioma

Cover of Holland-Frei Cancer Medicine
Holland-Frei Cancer Medicine. 5th edition.
Bast RC Jr, Kufe DW, Pollock RE, et al., editors.
Hamilton (ON): BC Decker; 2000.
© 2000, BC Decker Inc.

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.